Pharmacyte Biotech Stock Performance
| PMCB Stock | USD 1.58 0.09 5.39% |
PharmaCyte Biotech has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of 0.96, which implies possible diversification benefits within a given portfolio. PharmaCyte Biotech returns are very sensitive to returns on the market. As the market goes up or down, PharmaCyte Biotech is expected to follow. PharmaCyte Biotech right now holds a risk of 4.04%. Please check PharmaCyte Biotech treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to decide if PharmaCyte Biotech will be following its historical price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in PharmaCyte Biotech are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong fundamental indicators, PharmaCyte Biotech is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 68 M |
PharmaCyte |
PharmaCyte Biotech Relative Risk vs. Return Landscape
If you would invest 160.00 in PharmaCyte Biotech on December 22, 2024 and sell it today you would lose (2.00) from holding PharmaCyte Biotech or give up 1.25% of portfolio value over 90 days. PharmaCyte Biotech is currently generating 0.0577% in daily expected returns and assumes 4.0396% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than PharmaCyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PharmaCyte Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PharmaCyte Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PharmaCyte Biotech, and traders can use it to determine the average amount a PharmaCyte Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0143
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | PMCB | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.04 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average PharmaCyte Biotech is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PharmaCyte Biotech by adding it to a well-diversified portfolio.
PharmaCyte Biotech Fundamentals Growth
PharmaCyte Stock prices reflect investors' perceptions of the future prospects and financial health of PharmaCyte Biotech, and PharmaCyte Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PharmaCyte Stock performance.
| Return On Equity | 0.43 | ||||
| Return On Asset | -0.0505 | ||||
| Current Valuation | (5.29 M) | ||||
| Shares Outstanding | 6.87 M | ||||
| Price To Earning | 9.57 X | ||||
| Price To Book | 0.29 X | ||||
| EBITDA | 333.76 K | ||||
| Cash And Equivalents | 82.23 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 20.39 M | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (2.15 M) | ||||
| Earnings Per Share | 1.34 X | ||||
| Total Asset | 59.9 M | ||||
| Retained Earnings | (115.63 M) | ||||
| Current Asset | 1.6 M | ||||
| Current Liabilities | 449 K | ||||
About PharmaCyte Biotech Performance
By analyzing PharmaCyte Biotech's fundamental ratios, stakeholders can gain valuable insights into PharmaCyte Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PharmaCyte Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PharmaCyte Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Pharmacyte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.Things to note about PharmaCyte Biotech performance evaluation
Checking the ongoing alerts about PharmaCyte Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PharmaCyte Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PharmaCyte Biotech may become a speculative penny stock | |
| PharmaCyte Biotech had very high historical volatility over the last 90 days | |
| PharmaCyte Biotech has high likelihood to experience some financial distress in the next 2 years | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures |
- Analyzing PharmaCyte Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PharmaCyte Biotech's stock is overvalued or undervalued compared to its peers.
- Examining PharmaCyte Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PharmaCyte Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PharmaCyte Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PharmaCyte Biotech's stock. These opinions can provide insight into PharmaCyte Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |